A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
This study has been completed.
Sponsor:
Duramed Research
Information provided by:
Duramed Research
ClinicalTrials.gov Identifier:
NCT00196365
First received: September 12, 2005
Last updated: January 8, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary.
Condition | Intervention | Phase |
---|---|---|
Dysmenorrhea |
Drug: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets Drug: levonorgestrel/EE 0.15/0.03 mg tablets and placebo |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
Official Title: | A Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval Compared to Conventional Oral Contraceptive Therapy for Cyclic Pelvic Pain |
Resource links provided by NLM:
Further study details as provided by Duramed Research:
Primary Outcome Measures:
- Change from baseline in the clinical assessment of dysmenorrhea [ Time Frame: Baseline to Week 4,8,12,24, and 26 or early discontinuation ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Change from baseline in clinical assessment of dysmenorrhea (assessment of 4 additional symptoms) [ Time Frame: Baseline to Weeks 4, 8, 12, 24 and 26 or early discontinuation ] [ Designated as safety issue: No ]
- Incidence of menstrual bleeding and/or spotting [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
- Analgesic use [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
Enrollment: | 97 |
Study Start Date: | January 2005 |
Study Completion Date: | July 2007 |
Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1 |
Drug: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
1 tablet daily
Other Name: Seasonique
|
Active Comparator: 2 |
Drug: levonorgestrel/EE 0.15/0.03 mg tablets and placebo
1 tablet daily
Other Name: Portia
|
Eligibility
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Moderate to severe menstrual-related pain
- Regular spontaneous menstrual cycles
Exclusion Criteria:
- Any contraindication to the use of oral contraceptives
- Treatment with an oral contraceptive in the last 3 months
- Previous treatment failure with an extended oral contraceptive regimen
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00196365
Locations
United States, Alabama | |
Duramed Investigational Site | |
Huntsville, Alabama, United States, 35801 | |
United States, Arizona | |
Duramed Investigational Site | |
Phoenix, Arizona, United States, 85032 | |
United States, California | |
Duramed Investigational Site | |
San Diego, California, United States, 92108 | |
United States, Colorado | |
Duramed Investigational Site | |
Denver, Colorado, United States, 80202 | |
United States, Florida | |
Duramed Investigational Site | |
Tampa, Florida, United States, 33607 | |
United States, Georgia | |
Duramed Investigational Site | |
Decatur, Georgia, United States, 30034 | |
United States, New Jersey | |
Duramed Investigational Site | |
Moorestown, New Jersey, United States, 08057 | |
United States, North Carolina | |
Duramed Investigational Site | |
Charlotte, North Carolina, United States, 28222 | |
United States, Ohio | |
Duramed Investigational Site | |
Columbus, Ohio, United States, 43213 | |
Duramed Investigational Site | |
Columbus, Ohio, United States, 43205 | |
United States, Oregon | |
Duramed Investigational Site | |
Medford, Oregon, United States, 97504 | |
United States, Pennsylvania | |
Duramed Investigational Site | |
Philadelphia, Pennsylvania, United States, 19114 | |
United States, Tennessee | |
Duramed Investigational Site | |
Memphis, Tennessee, United States, 38120 | |
United States, Utah | |
Duramed Investigational Site | |
Salt Lake City, Utah, United States, 84124 | |
United States, Virginia | |
Duramed Investigational Site | |
Newport News, Virginia, United States, 23602 | |
Duramed Investigational Site | |
Norfolk, Virginia, United States, 23507 | |
United States, Washington | |
Duramed Investigational Site | |
Spokane, Washington, United States, 99207 | |
Duramed Investigational Site | |
Tacoma, Washington, United States, 98405 |
Sponsors and Collaborators
Duramed Research
Investigators
Study Chair: | Duramed Protocol Chair | Duramed Research, Inc. |
More Information
No publications provided
Keywords provided by Duramed Research:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
No publications provided
Responsible Party: | Duramed Protocol Chair, Duramed Research, Inc. |
ClinicalTrials.gov Identifier: | NCT00196365 History of Changes |
Other Study ID Numbers: | DR-PSE-305 |
Study First Received: | September 12, 2005 |
Last Updated: | January 8, 2010 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by Duramed Research:
cyclic pelvic pain dysmenorrhea |
Additional relevant MeSH terms:
Dysmenorrhea Pelvic Pain Menstruation Disturbances Pathologic Processes Pain Signs and Symptoms Contraceptives, Oral Levonorgestrel Ethinyl estradiol, levonorgestrel drug combination |
Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses Contraceptives, Oral, Synthetic Contraceptives, Oral, Combined |
ClinicalTrials.gov processed this record on October 16, 2012